IGM Biosciences is a clinical-stage biotechnology company engaging in the development of Immunoglobulin M (IgM) antibodies for the treatment of cancer, autoimmune and inflammatory diseases and infectious diseases. Co.'s product candidates include: IGM-8444, which is an IgM antibody targeting Death Receptor 5 proteins for the treatment of patients with solid and hematologic malignancies; Imvotamab, which is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins; IGM-7354, which is an IgM antibody targeting the delivery of interleukin-15 to the area of PD-L1 expressing cells; and IGM-2644, which is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins. The IGMS YTD return is shown above.
The YTD Return on the IGMS YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether IGMS YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the IGMS YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|